But wait there's more. GLP-1s continue to bring miracles.
The new study, "Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis" (Vatsia et al., PMID: 40042198), dives into the impact of GLP-1 agonist therapy on pseudarthrosis rates in multilevel cervical spine fusion. Given the growing use of GLP-1 agonists like semaglutide and liraglutide for managing obesity and diabetes—conditions often seen in our patient population—this retrospective analysis is highly relevant to the fusion space.
PubMed article - Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis
Using the TriNetX Diamond Network database, the authors pulled data from 2005 to 2024, focusing on patients undergoing anterior and posterior multilevel cervical fusions (identified via CPT codes). They split the cohort into two groups: those prescribed GLP-1 agonists (e.g., liraglutide, tirzepatide, dulaglutide) within a year of surgery and those who weren’t. To control for confounders, they propensity-matched the groups based on age, sex, race, nicotine use, BMI, and HbA1c—key variables we know influence fusion outc...
